Share This Page

 
Now on Twitter!

Follow us: ChinaBio

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Free White Paper

Simcere’s Q2 Revenue Below Expectations

publication date: Aug 5, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Simcere Pharmaceutical Group reported significantly improved Q2 financials today, but the results came in below analysts' estimates and the company reduced its guidance for full-year 2008. The disappointments caused a 4% selloff in the company’s stock price. Simcere blamed the shortfall on two problems: Endu revenue growth was lower than expected because the company restructured its Endu sales force. Also, Simcere is giving away Endu to accelerate participation in a Phase IV clinical trial of the drug, resulting in lower-than-projected sales. More details...

Stock Symbol: (NYSE: SCR)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

  

    
   
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Partner Events

China Healthcare Investment Conference 2012
March 13-15, 2012
Shanghai, China


Shanghai CEO Conference
March 28-29, 2012
Shanghai, China

>>More details...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners